<?xml version="1.0" encoding="UTF-8"?>
<p>By the beginning of May 2020, hundreds of clinical trials are being conducted worldwide to find effective pharmacotherapy and develop a vaccine to conquer SARS-CoV-2, which was summarized here (
 <xref ref-type="supplementary-material" rid="S1">Supplementary Material 1</xref>, 
 <ext-link ext-link-type="uri" xlink:href="http://www.jocmr.org" xmlns:xlink="http://www.w3.org/1999/xlink">www.jocmr.org</ext-link>) [
 <xref rid="R84" ref-type="bibr">84</xref>]. Approximately 12 clinical trials with therapeutic intervention are completed and results are pending for most of them apart from the clinical trial from Hong Kong which published results recently. A phase 2 clinical trial involving IFN beta-1b, lopinavir/ritonavir, mainly used for the treatment of HIV, ribavirin mainly used in combination with IFN for the treatment of hepatitis C was tested in 86 patients for 14 days for treatment of COVID-19 in Hong Kong. The treatment group took all the above medications while the control group took lopinavir/ritonavir. The patient is in the active intervention group, and the control group had viral clearance at an average of 7 days and 12 days, respectively. The combination of medications was well tolerated, with no severe side effects [
 <xref rid="R85" ref-type="bibr">85</xref>].
</p>
